News
10-08-2016, 06:35 AM
The addition of the CDK4/6 inhibitor ribociclib to letrozole therapy significantly improves progression-free survival in postmenopausal women with hormone receptor-positive advanced breast cancer, researchers reported today at the ESMO 2016 Congress in Copenhagen.
More... (http://www.news-medical.net/news/20161008/Combination-treatment-with-CDK46-inhibitor-improves-progression-free-survival-in-HR2b-breast-cancer-patients.aspx)
More... (http://www.news-medical.net/news/20161008/Combination-treatment-with-CDK46-inhibitor-improves-progression-free-survival-in-HR2b-breast-cancer-patients.aspx)